Pipeline Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update BioPharma DiveImmunovant shares climbed on results an analyst deemed compelling in tough-to-treat arthritis.Immunology & InflammationRead full story pharminent May 20, 2026 (Last updated: May 20, 2026) BioPharma Dive Immunovant shares climbed on results an analyst deemed compelling in tough-to-treat arthritis. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pazdur declines to announce candidacy for vacated FDA commissioner role Related Stories Pipeline Genmab drops 2 antibody assets, including another ProfoundBio ADC pharminent May 15, 2026 Pipeline Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism pharminent May 14, 2026 Pipeline Amgen positions MariTide as potential ‘best monthly’ obesity drug pharminent May 1, 2026
